Terminated PHASE1 INTERVENTIONAL 2-arm NCT01329744

Effects of IGF-I in HIV Metabolic Disease

Effects of Recombinant IGF-I in HIV Associated Metabolic Disease

Sponsor: University of Texas Southwestern Medical Center

Interventions Placebo control mecasermin

Updated 6 times since 2017 Last updated: Mar 22, 2016 Started: Jun 30, 2011 Primary completion: Jun 30, 2013 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from University of Texas Southwestern Medical Center

See all terminations from University of Texas Southwestern Medical Center

This PHASE1 trial investigates HIV Lipodystrophy and is currently terminated or withdrawn. University of Texas Southwestern Medical Center leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Texas Southwestern Medical Center

Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States